1. A MRD‐GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). (June 2017) Authors: Ghia, P.; Scarfò, L.; Coscia, M.; Sancetta, R.; Ferrario, A.; Tedeschi, A.; Farina, L.; Laurenti, L.; Orlandi, E.; Reda, G.; Motta, M.; Carlo Stella, C.; Massaia, M.; Quaresmini, G.; Rossini, F.; Ladetto, M.; Gaidano, G.; Rossi, V.; Montillo, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS. (23rd June 2022) Authors: Oliva, E. N.; Salutari, P.; Di Raimondo, F.; Reda, G.; Capelli, D.; Iannì, G.; Tripepi, G.; Alati, C.; Mammì, C.; D'Errigo, M. G.; Niscola, P.; Selleri, C.; Musto, P.; Vigna, E.; Volpe, A.; Cascavilla, N.; Cannatà, M. C.; Mannina, D.; Candoni, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE. (23rd June 2022) Authors: Bomben, R.; Rossi, F. M.; Vit, F.; Bittolo, T.; Zucchetto, A.; Papotti, R.; Tissino, E.; Pozzo, F.; Degan, M.; Zaina, E.; Cattarossi, I.; Nanni, P.; Marasca, R.; Reda, G.; Laurenti, L.; Olivieri, J.; Chiarenza, A.; Ballotta, L.; Cuneo, A.; Gentile, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P659: IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT. (23rd June 2022) Authors: Reda, G.; Mattiello, V.; Frustaci, A. M.; Visentin, A.; Mauro, F. R.; Innocenti, I.; Gentile, M.; Giannarelli, D.; Noto, A.; Cassin, R.; Laurenti, L.; Tedeschi, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 557 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. (23rd June 2022) Authors: Mauro, F. R.; Giannarelli, D.; Galluzzo, C.; Visentin, A.; Frustaci, A. M.; Sportoletti, P.; Vitale, C.; Reda, G.; Gentile, M.; Levato, L.; Murru, R.; Armiento, D.; Ielo, C.; Maglione, R.; Crisanti, E.; Cipiciani, A.; Mattiello, V.; Gianfelici, V.; Barabino, L.; Amici, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. (23rd June 2022) Authors: Garcia-Manero, G.; Bart, S.; McCloskey, J. K.; Fenaux, P.; Selleslag, D.; Reda, G.; Valcárcel, D.; Santini, V.; Mayer, J.; Xicoy, B.; Yamaguchi, H.; Lübbert, M.; Miyazaki, Y.; Keer, H.; Hao, Y.; Azab, M.; Döhner, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations. Issue 6 (2nd June 2016) Authors: Reda, G.; Orofino, N.; Cassin, R.; Sciumè, M.; Fattizzo, B.; Cortelezzi, A. Journal: Expert opinion on drug safety Issue: Volume 15:Issue 6(2016) Page Start: 865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗